Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for ...

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

AppLovin is the IBD Stock Of The Day as the mobile app marketing platform rises ahead of its fourth-quarter report.

Novo Nordisk's experimental obesity drug amycretin demonstrated promising weight loss results in an early-stage trial, with participants losing 22% of their body weight in 36 weeks. This news boosted ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... I consider this temporary dip in stock price as an excellent buying opportunity, and I am putting a "Buy" rating on LLY, with the company's ...